ResearchIn-Press PreviewAIDS/HIVImmunologyInfectious disease
Open Access |
10.1172/jci.insight.193752
1Emory Vaccine Center, Emory University, Atlanta, United States of America
2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America
3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America
Find articles by Sadagopal, S. in: PubMed | Google Scholar
1Emory Vaccine Center, Emory University, Atlanta, United States of America
2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America
3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America
Find articles by Stokdyk, K. in: PubMed | Google Scholar
1Emory Vaccine Center, Emory University, Atlanta, United States of America
2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America
3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America
Find articles by Kwa, S. in: PubMed | Google Scholar
1Emory Vaccine Center, Emory University, Atlanta, United States of America
2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America
3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America
Find articles by Basu, R. in: PubMed | Google Scholar
1Emory Vaccine Center, Emory University, Atlanta, United States of America
2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America
3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America
Find articles by Gangadhara, S. in: PubMed | Google Scholar
1Emory Vaccine Center, Emory University, Atlanta, United States of America
2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America
3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America
Find articles by Ahmed, R. in: PubMed | Google Scholar
1Emory Vaccine Center, Emory University, Atlanta, United States of America
2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America
3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America
Find articles by Iyer, S. in: PubMed | Google Scholar
1Emory Vaccine Center, Emory University, Atlanta, United States of America
2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America
3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America
Find articles by Araki, K. in: PubMed | Google Scholar
1Emory Vaccine Center, Emory University, Atlanta, United States of America
2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America
3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America
Find articles by
Amara, R.
in:
PubMed
|
Google Scholar
|
Published April 23, 2026 - More info
Inhibiting the mammalian target of rapamycin (mTOR) during acute viral infection generates highly functional memory CD8 T cells. We investigated the effects of inhibiting mTOR by using rapamycin during the effector and contraction phases of the immune response to a DNA prime and Modified Vaccinia Ankara (MVA) boost SIV vaccination in rhesus macaques. Rapamycin administered either during MVA boosts alone (DMR) or during both primes and boosts (DRMR) reduced the contraction of effector CD8 T cells, resulting in higher frequencies of SIV-specific memory CD8 T cells with enhanced quality as indicated by expression of Bcl-2 and CD127. Additionally, rapamycin reduced the frequency of proliferating CCR5+ CD4 T cells in the blood following the MVA boost. Post SIV251 infection, rapamycin-treated macaques demonstrated marked expansion of SIV-specific CD8 T cells (reaching up to 50% in blood and 25% in gut). The heightened expansion of SIV-specific CD8 T cells in the DMR group was associated with markedly lower (2-logs compared to unvaccinated and 1-log compared to DM) peak viral load in the gut and set-point viremia, along with improved survival post infection. Thus, inhibiting the mTOR pathway during MVA boosts of a DNA/MVA vaccine enhances vaccine efficacy by improving memory CD4 and CD8 T cell function.